natgillin/translations-raw huggingface dataset:
Marketing Authorisation Holder: MedImmune, LLC, Lagelandseweg 78, 6545 CG Nijmegen, Netherlands, (Tel) +31 24 371 7310 
MedImmune, LLC Lagelandseweg 78 6545 CG Nijmegen Nizozemska (tel) +31 24 371 7310
Talk to your doctor, nurse or pharmacist before vaccination: 
Pred cepljenjem se posvetujte s svojim zdravnikom, medicinsko sestro ali farmacevtom:
Contains also: sucrose, dibasic potassium phosphate, monobasic potassium phosphate, gelatin (porcine, Type A), arginine hydrochloride, monosodium glutamate monohydrate, water for injections. 
Vsebuje tudi: saharozo, kalijev hidrogenfosfat, kalijev dihidrogenfosfat, želatino (svinjsko, tipa A), argininijev klorid, natrijev glutamat monohidrat, vodo za injekcije.
Fluenz must only be used as a nasal spray. 
Cepivo Fluenz se lahko uporablja le v obliki pršila za nos.
QUALITATIVE AND QUANTITATIVE COMPOSITION Reassortant influenza virus* (live attenuated) of the following strains**: A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Novi virus gripe* (živ oslabljen) naslednjih sevov**: A/California/7/2009 (H1N1)pdm09-podoben sev (A/California/7/2009, MEDI 228029)
If any of these apply, tell your doctor, nurse or pharmacist. 
Če karkoli od tega velja za vas, obvestite svojega zdravnika, medicinsko sestro ali farmacevta.
Efficacy (95% CI)b Matched strains 
Učinkovitost (95-% IZ)b Ujemajoči se sevi
Reassortant influenza virus* (live attenuated) of the following strains**: A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 
Novi virus gripe* (živ oslabljen) naslednjih sevov**: A/California/7/2009 (H1N1)pdm09-podoben sev (A/California/7/2009, MEDI 228029)
Dibasic potassium phosphate Monobasic potassium phosphate Gelatin (porcine, Type A) Arginine hydrochloride Monosodium glutamate monohydrate Water for injections 
6.1 Seznam pomožnih snovi saharoza kalijev hidrogenfosfat kalijev dihidrogenfosfat želatina (svinjska, tip A) argininijev klorid natrijev glutamat monohidrat voda za injekcije
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS PACK SIZE OF 5 SINGLE-USE NASAL APPLICATORS 
VELIKOST PAKIRANJA 5 NOSNIKOV ZA ENKRATNO UPORABO
- If any of the side effects gets serious, talk to your doctor, nurse or pharmacist. 
- Če katerikoli neželeni učinek postane resen, se posvetujte s svojim zdravnikom, medicinsko sestro ali farmacevtom.
The other ingredients are sucrose, dibasic potassium phosphate, monobasic potassium phosphate, gelatin (porcine, Type A), arginine hydrochloride, monosodium glutamate monohydrate and water for injections. 
Pomožne snovi so saharoza, kalijev hidrogenfosfat, kalijev dihidrogenfosfat, želatina (svinjska, tipa A), argininijev klorid, natrijev glutamat monohidrat in voda za injekcije.
The co-administration of FLUENZ with the live attenuated vaccines: measles, mumps, rubella, varicella, and orally-administered poliovirus has been studied. 
Preučili so sočasno uporabo cepiva FLUENZ z živimi oslabljenimi cepivi proti ošpicam, mumpsu, rdečkam, noricam in peroralnim cepivom proti otroški paralizi.
METHOD OF ADMINISTRATION For nasal use only. 
POSTOPEK UPORABE Samo za nazalno uporabo.
fewer cases than injectable 
manj primerov kot pri cepivu, ki se injicira d manj primerov kot pri cepivu, ki se injicira
STATEMENT OF ACTIVE SUBSTANCE(S) Reassortant influenza virus* (live attenuated) of the following strains**: A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Novi virus gripe* (živ oslabljen) naslednjih sevov**: A/California/7/2009 (H1N1)pdm09-podoben sev (A/California/7/2009, MEDI 228029)
Fluenz nasal spray suspension Influenza vaccine (live attenuated, nasal) 
FLUENZ pršilo za nos, suspenzija cepivo proti gripi (z živimi oslabljenimi virusi, nosno)
USA 
Združene države Amerike (ZDA)
Method of administration Immunisation must be carried out by nasal administration. 
Način uporabe Imunizacija se opravi z nazalno uporabo.
Nasal spray, suspension 
FARMACEVTSKA OBLIKA pršilo za nos, suspenzija
Do not pass it on to others. 
Napršite v drugo
6 to 35 M 2,107 
6 do 35 m 1.616
D153-P513 Asia/ Oceania 
D153-P513 Azija/ Oceanija 6 do 35 m 2.107
remove the dose-divider clip from plunger. 
Odstranite sponko za razdelitev odmerka Za vnos v drugo nosnico odščipnite in odstranite sponko za razdelitev odmerka z bata.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SINGLE-USE NASAL APPLICATOR 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Packaging Content Package size Withdrawal period 
Vrsta ovojnine Vsebina Pakiranje Karenca
EU number Invented name 
Izmišljeno ime
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO VPELJATI DRŽAVE ČLANICE
ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
PRILOGA POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO VPELJATI DRŽAVE ČLANICE
ATCvet code: QM01AH90. 
ATCvet oznaka: QM01AH90.
4.6 Adverse reactions (frequency and seriousness)* 
4.6 Neželeni učinki (pogostost in resnost)*
Tablets can be administered with or without food. 
Tablete lahko dajemo s hrano ali brez.
Date of first authorisation: 13/09/2004 Date of last renewal: 29/05/2009 
Datum pridobitve dovoljenja za promet: 13.09.2004 Datum podaljšanja dovoljenja za promet: 29.05.2009
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/
Peri-operative pain management. 
Peri-operativno obvladovanje bolečine.
Firocoxib is approximately 96 % bound to plasma proteins. 
Firokoksib se v približno 96 % veže na plazemske proteine.
4 Chemin de Calquet 31000 Toulouse France 
4 chemin du Calquet 31000 TOULOUSE FRANCIJA
The elimination half-life (t½) is 7.59 (± 1.53) hours. 
Razpolovna doba izločanja (t½) je 7,59 (± 1,53) ur.
Relief of post-operative pain: 
Lajšanje post-operativne bolečine:
Iron oxides (E172) Caramel (E150d) 
Železov oksid (E172) Karamel (E150d)
Duration of treatment will be dependent on the response observed. 
Čas trajanja zdravljenja je odvisen od odziva.
Very rare (affects less than 1 animal in 10,000) 
Redki (prizadenejo 1 do 10 živali od 10.000 živali) Zelo redki (prizadenejo manj kot eno žival od 10.000 živali)
Overdose studies were not conducted in animals over 14 months of age. 
Raziskave na psih starejših od 14 mesecev niso bile izvedene.
Manufacturer for the batch release: MERIAL, 4 Chemin du Calquet, 31000 Toulouse, France 
Izdelovalec, odgovoren za sprostitev serije: MERIAL, 4 Chemin du Calquet, 31000 Toulouse, Francija
Firocoxib 
Firokiksib
10 tablets 30 tablets 60 tablets 180 tablets 
10 tablet 30 tablet 60 tablet 180 tablet
If such use cannot be avoided, those dogs require careful veterinary monitoring. 
Če se uporabi v takih primerih ne moremo izogniti, je potreben strog veterinarski nadzor.
The chewable tablets (57 mg or 227 mg) are available in the following pack sizes: 
Žvečljive tablete (57 mg ali 227 mg) so na voljo v naslednjih pakiranjih:
These reactions are generally of a transitory nature and are reversible when the treatment is stopped. 
Te reakcije so običajno prehodnega značaja in minejo, ko prenehamo z zdravljenjem.
Mode of action: 
Način delovanja:
The peak concentration (Cmax) is 0.52 (± 0.22) µg/ml (equivalent to approximately 1.5 µM), area under the curve (AUC 0-24) is 4.63 (±1.91) µg x hr/ml, and oral bioavailability is 36.9 (± 20.4) percent. 
Najvišja vrednost koncentracije (Cmax) je 0,52 (± 0,22) µg/ml (kar ustreza približno 1,5 µM), površina pod krivuljo (AUC 0-24) je 4,63 (± 1,91) µg xhr/ml, in oralna biorazpoložljivost je 36,9 (± 20,4) %.
For oral use as per table below. 
Za peroralno uporabo v skladu s spodaj navedeno tabelo.
Lactose Monohydrate Microcrystalline Cellulose Chartor Hickory Smoke Flavour Hydroxypropyl Cellulose Croscarmellose Sodium Magnesium Stearate Caramel (E150d) Silica, colloidal anhydrous Iron Oxides (E172) 
Laktoza monohidrat Celuloza, mikrokristalna Chartor dimni hikori okus Hidroksipropilceluloza Natrijev karmelozat, premreženi Magnezijev stearat Kramel (E150d)
Cyclooxygenase is responsible for generation of prostaglandins. 
Ciklooksigenaza je odgovorna za sintezo prostaglandinov.
5 mg/kg once daily. 
Enkrat dnevno 5 mg/kg.
Do not use in animals suffering from gastrointestinal bleeding, blood dyscrasia or haemorrhagic disorders. 
Ne uporabite pri živalih s krvavitvami v prebavilih, z motnjami v sestavi krvi ali hemoragičnimi obolenji.
5.2 Pharmacokinetic particulars 
5.2 Farmakokinetične lastnosti
Previcox tablets are supplied in blisters (transparent PVC /aluminium foil) or in 30 ml or 100 ml high density polyethylene bottles (with polypropylene closure). 
Previcox tablete so v pretisnih omotih (prozorni PVC/aluminijasta folija) - ali 30 ml in 100 ml polietilenskih plastičnih vsebnikih (s polipropilenskim pokrovom).
Concomitant treatment with molecules displaying action on renal flow, e.g. diuretics or Angiotensin Converting Enzyme (ACE) inhibitors, should be subject to clinical monitoring. 
Sočasno zdravljenje z molekulami, ki vplivajo na pretok skozi ledvice npr. diuretiki ali inhibitorji angiotenzin konvertaze (ACE), mora biti pod strogim veterinarskim nadzorom.
For the reduction of post-operative pain and inflammation, the animals can be dosed starting approximately 2 hours before surgery for up to 3 consecutive days as needed. 
Za zmanjšanje post-operativne bolečine in vnetja lahko damo živalim prvi odmerek približno 2 uri pred operativnim posegom in po potrebi nadaljujemo zdravljenje še do 3 zaporedne dni.
Following orthopaedic surgery and depending on the response observed, treatment using the same daily dosing schedule may be continued after the first 3 days, upon judgement of the attending veterinarian. 
Po ortopedskih operativnih posegih lahko, glede na opaženo uspešnost zdravljenja bolečine, enako odmerjanje nadaljujemo tudi po prvih treh dneh po posegu po presoji odgovornega veterinarja.
Do not use in animals less than 10 weeks of age or less than 3 kg body weight. 
Ne uporabite pri živalih mlajših od 10 tednov in lažjih od 3 kg telesne mase.
Following oral administration in dogs at the recommended dose of 5 mg per kg of bodyweight, firocoxib is rapidly absorbed and the time to maximal concentration (Tmax) is 1.25 (± 0.85) hours. 
Po peroralnem dajanju zdravila pri psih v priporočenem odmerku 5 mg na kg telesne mase se firokoksib hitro absorbira in v 1,25 (± 0,85) urah doseže maksimalno koncentracijo(Tmax).
Firocoxib is metabolised predominantly by dealkylation and glucuronidation in the liver. 
Firokoksib se presnavlja večinoma z dealkilizacijo in glukoronidacijo v jetrih.
Appropriate laboratory testing is recommended prior to treatment in order to detect subclinical (asymptomatic) renal or hepatic disorders that may predispose to adverse effects. 
Pred pričetkom zdravljenja so priporočljive ustrezne laboratorijske preiskave za ugotovitev morebitnih obstoječih subkliničnih (asimptomatskih) ledvičnih ali jetrnih obolenj, ki lahko povečajo možnosti za pojav stranskih učinkov.
Administer 5 mg per kg bodyweight once daily as presented in the table below. 
Odmerek je 5 mg na kg telesne mase enkrat dnevno kot je prikazano v spodnji tabeli.
Following multiple oral administrations, the steady state is reached by the third daily dose. 
Po večkratnem peroralnem dajanju doseže ustaljeno stanje s tremi dnevnimi odmerki.
Previcox Chewable tablets are scored to facilitate accurate dosing and contain caramel and smoke flavours to facilitate administration to dogs. 
Previcox žvečljive tablete omogočajo natančno odmerjanje, okus karamela in dima pa olajša dajanje tablet psom.
As with other NSAIDs, serious adverse effects can occur and, in very rare cases, may be fatal. 
Kot pri drugih NSAID se lahko pojavijo resni neželeni učinki, ki so izjemoma lahko smrtni.
- 1 cardboard box containing 10 tablets in one blister - 1 cardboard box containing 30 tablets in three blisters - 1 cardboard box containing 180 tablets in eighteen blisters - 1 cardboard box containing 60 tablets in one bottle 
- 1 škatla z 10 tabletami v enem pretisnem omotu - 1 škatla s 30 tabletami v treh pretisnih omotih - 1 škatla s 180 tabletami v 18 pretisnih omotih - 1 škatla s 60 tabletami
Previcox must not be administered in conjunction with other NSAIDs or glucocorticosteroids. 
Zdravila Previcox ne smete uporabljati skupaj z drugimi NSAID ali glukokortikoidi.
The concentration of firocoxib required to inhibit 50 % of the COX-2 enzyme (i.e., the IC50) is 0.16 (± 0.05) µM, whereas the IC50 for COX-1 is 56 (± 7) µM. 
50 odstotno inhibicijo COX-2 encima (t.j IC50) dosežemo s koncentracijo 0,16 (± 0,05) µM firokoksiba, medtem ko IC50 za COX-1 znaša 56 (± 7) µM.
As field studies were limited to 90 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the veterinarian. 
Ker se podatki raziskav v praksi nanašajo na omejeno obdobje 90 dni, mora biti dolgotrajno zdravljenje pod veterinarskim nadzorom.
Coxibs therefore display analgesic, anti-inflammatory and antipyretic properties. 
Koksibi imajo protibolečinske, protivnetne in anti piretične lastnosti.
In dogs ten weeks of age at the start of treatment at dose rates equal or greater to 25 mg/kg/day (5 times the recommended dose) for three months, the following signs of toxicity were observed: bodyweight loss, poor appetite, changes in the liver (accumulation of lipid), brain (vacuolisation), duodenum (ulcers) and death. 
Pri psih, ki so bili ob začetku raziskave stari 10 tednov, so se po treh mesecih prejemanja odmerkov enakih ali višjih od 25 mg/kg/dan (petkratni priporočeni odmerek) pojavila naslednja znamenja toksičnosti: izguba telesne mase, slabši apetit, spremembe v jetrih (nakopičenje lipidov), možganih (vakuolizacija), dvanajstniku (razjede) in pogin živali.
Therefore, appropriate laboratory testing to establish baseline renal or hepatic biochemistry parameters is recommended prior to and periodically during administration. 
Zato so priporočljive laboratorijske preiskave za določitev osnovnih ledvičnih ali jetrnih biokemijskih vrednosti pred in med dajanjem zdravila.
COX-2 is also thought to be involved in ovulation, implantation and closure of the ductus arteriosus, and central nervous system functions (fever induction, pain perception and cognitive function). 
COX - 2 naj bi sodeloval tudi pri ovulaciji, implantaciji in zaprtju ductusa arteriosusa, ter pri delovanju centralnega živčnega sistema (sprožitev povišane telesne temperature,
EU/2/04/045/001 10 tablets EU/2/04/045/002 30 tablets EU/2/04/045/005 180 tablets EU/2/04/045/008 60 tablets 
EU/2/04/045/001 10 tablet EU/2/04/045/002 30 tablet EU/2/04/045/005 180 tablet EU/2/04/045/008 60 tablet
It is possible that a proportion of such cases had sub-clinical renal or hepatic disease prior to the commencement of therapy. 
Verjetno je del teh živali imel obstoječe subklinične oblike ledvičnih ali jetrnih obolenj pred pričetkom zdravljenja.
EU/2/04/045/003 10 tablets EU/2/04/045/004 30 tablets EU/2/04/045/006 180 tablets EU/2/04/045/009 60 tablets 
EU/2/04/045/003 10 tablet EU/2/04/045/004 30 tablet EU/2/04/045/006 180 tablet EU/2/04/045/009 60 tablet
Tan-brown, round, convex, engraved scored tablets. 
Rumeno rjave barve, okrogle, konveksne tablete z vtisnjeno oznako.
To be supplied only on veterinary prescription. 
Izdaja zdravila je le na veterinarski recept
As anaesthetic drugs may affect renal perfusion, the use of parenteral fluids during surgery should be considered to decrease potential renal complications when using NSAIDs peri-operatively. 
Ker lahko anestetiki vplivajo na perfuzijo ledvic, je med operativnimi posegi priporočljivo parenteralno nadomeščanje tekočin, da se ob perioperativni uporabi NSAID zmanjša možnost nastanka ledvičnih zapletov.
Keep out of the reach and sight of children. 
Izogibajte se stiku z očmi in kožo.
Concurrent use of other active substances that have a high degree of protein binding may compete with firocoxib for binding and thus lead to toxic effects. 
Ob sočasni uporabi drugih zdravilnih učinkovin, ki se dobro vežejo na plazemske proteine, lahko pride do kompetitivnosti pri vezavi s firokoksibom in posledično do toksičnih učinkov.
Rarely, nervous system disorders have been reported in treated dogs. 
Redko so bile pri zdravljenih psih opisane motnje v delovanju živčnega sistema.
If clinical signs of overdosing are observed, discontinue treatment. 
Ob pojavu znamenj prekomernega odmerjanja, takoj prenehajte z zdravljenjem.
Not all pack sizes may be marketed. 
Ni nujno, da so v prometu vsa navedena pakiranja
Body weight (kg) Number of chewable tablets by size mg/kg range 
Število žvečljivih tablet glede na njihovo velikost mg/kg obseg
In case of accidental ingestion, seek medical advice immediately and show the package insert or the label to the physician. 
V primeru nenamernega zaužitja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
EXP {month/year} Half tablets should be returned to the original market container and may be stored for up to 7 days. 
EXP {mesec/leto} Razpolovljene tablete vrnjene v originalno embalažo lahko hranite največ sedem dni.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there is a risk of increased renal toxicity. 
Izogibajte se uporabi tega zdravila pri dehidriranih, hipovolemičnih in hipotenzivnih živalih, ker obstaja povečano tveganje za ledvice.
Firocoxib is a non-steroidal anti-inflammatory drug (NSAID) that acts by selective inhibition of cyclooxygenase-2 (COX-2) - mediated prostaglandin synthesis. 
Firokoksib je nesteroidno protivnetno zdravilo (NSAID), selektivno zavira delovanje ciklooksigenaze-2 (COX-2) v sintezi prostaglandinov.
At dose rates equal or greater to 15 mg/kg/day (3 times the recommended dose) for six months, similar clinical signs were observed, albeit that the severity and frequency were less and duodenal ulcers were absent. 
Podobna klinična znamenja so se pojavila po šestih mesecih pri odmerkih višjih od 15 mg/kg/dan, (trikratni priporočeni odmerek), čeprav so bila manj resna, manj pogosta in ni bilo razjed dvanajstnika.
Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids. 
Farmakoterapevtska skupina: Nesteroidna protivnetna in protirevmatična zdravila
Firocoxib is a non-steroidal anti-inflammatory drug (NSAID) belonging to the Coxib group, which acts by selective inhibition of cyclooxygenase-2 (COX-2) - mediated prostaglandin synthesis. 
Firokoksib je nesteroidno protivnetno zdravilo (NSAID), ki pripada skupini koksibov, in ki selektivno zavirajo delovanje ciklooksigenaze-2 (COX-2) v sintezi prostaglandinov.
For the relief of post-operative pain and inflammation associated with soft-tissue, orthopaedic and dental surgery in dogs. 
Za lajšanje post-operativne bolečine in blaženje vnetja, povezanih z operativnimi posegi na mehkih tkivih, ortopedskimi operativnimi posegi in zobni kirurgiji pri psih.
In dogs seven months of age at the start of treatment at dose rates greater than or equal to 25 mg/kg/day (5 times the recommended dose) for six months, gastrointestinal adverse effects, i.e. vomiting were observed. 
Pri psih, ki so bili ob začetku raziskave stari 7 mesecev in so šest mesecev prejemali odmerke 25 mg/kg/dan ali višje (petkratni priporočeni odmerek), niso opazili stranskih učinkov v prebavilih t.j.
Do not use in pregnant or lactating bitches. 
Ne uporabite pri psicah v obdobju brejosti in laktacije.
Laboratory studies in rabbits have shown evidence of maternotoxic and foetotoxic effects at dose rates approximating the recommended treatment dose for the dog. 
Laboratorijske raziskave na kuncih z vnosom priporočenih odmerkov za pse so pokazale maternotoksične in fetotoksične učinke.
If adverse reactions like vomiting, repeated diarrhoea, faecal occult blood, sudden weight loss, anorexia, lethargy, degradation of renal or hepatic biochemistry parameters occur, use of the product should be stopped and the advice of a veterinarian should be sought. 
Če se pojavijo stranski učinki kot je bruhanje, ponavljajoča se driska, kri v blatu, nenadna izguba telesne mase, anoreksija, letargičnost, spremenjene vrednosti biokemičnih parametrov ledvic ali jeter, takoj prenehajte z uporabo tega zdravila in poiščite veterinarsko pomoč.
Half tablets should be returned to the original market container and may be stored for up to 7 days. 
Razpolovljene tablete vrnjene v originalno embalažo lahko hranite največ 7 dni.
Renal and/or hepatic disorders have been reported in very rare cases in dogs administered the recommended treatment dose. 
Zelo redko so poročali o ledvičnih in/ali jetrnih obolenjih pri psih, zdravljenih s priporočenimi odmerki.
In in-vitro canine whole blood assays, firocoxib exhibits approximately 380-fold selectivity for COX-2 over COX-1. 
Raziskave krvi pri psu in vitro so pokazale, da firokoksib 380 krat bolj selektivno deluje na COX-2 kot na COX-1.
A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA
Administer 5 mg per kg bodyweight once daily. 
Enkrat dnevno dajte 5 mg na kg telesne mase.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Bottle label 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Firocoxib 227 mg 
Firokoksib 227 mg
For the relief of pain and inflammation associated with osteoarthritis in dogs. 
Za blažitev bolečin in vnetja, ki so povezani z osteoartritisom pri psih.
Special precautions for use in animals The recommended dose, as indicated in the dosing table, should not be exceeded. 
Ne prekoračite priporočenega odmerka, ki je naveden v tabeli odmerkov.
COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. 
Predvnetni dražljaj sproži nastanek COX-2 izoformne oblike encima, ki je po ugotovitvah prvotno odgovoren za sintezo prostanoidnih mediatorjev bolečine, vnetja in povišane telesne temperature.
Name and address of the manufacturer responsible for batch release 
SPROŠČANJE SERIJE Ime in naslov izdelovalca zdravila, odgovornega za sproščanje serije
COX-2 is the isoform of the enzyme that has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. 
COX-2 izoformna oblika encima je po nekaterih ugotovitvah prvotno odgovorna za sintezo prostanoidnih mediatorjev bolečine, vnetja in povišane telesne temperature.
*The frequency of possible adverse effects is defined using the following convention: Rare (affects 1 to 10 animals in 10,000) 
*Pogostost pojavljanja neželenih učinkov določa naslednja konvencija:
The treatment should be discontinued if any of these signs are observed: repeated diarrhoea, vomiting, faecal occult blood, sudden weight loss, anorexia, lethargy, degradation of renal or hepatic biochemistry parameters. 
Če se pojavijo stranski učinki kot so bruhanje, ponavljajoča se driska, kri v blatu, nenadna izguba telesne mase, anoreksija, letargičnost, spremenjene vrednosti biokemičnih parametrov ledvic ali jeter,
Gastrointestinal tract ulceration may be exacerbated by corticosteroids in animals given non-steroidal anti-inflammatory drugs. 
Pri psih zdravljenih z nesteroidnimi protivnetnimi zdravili se lahko na prebavilih stanje razjed povzročenih s kortikosteroidi poslabša.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. 
Pri določitvi časa, ki mora miniti od prenehanja zdravljenja s prejšnjim zdravilom in pričetkom zdravljenja z zdravilom Previcox,, moramo upoštevati farmakokinetične lastnosti prejšnjega zdravila.